Company news
Hoth Therapeutics, Inc. news in 2022
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
December 28, 2022
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules
December 28, 2022
Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001
November 30, 2022
HOTH Therapeutics reports positive BioLexa phase 1B clinical trial results in mild to moderate atopic dermatitis
October 30, 2022
Hoth Therapeutics Announces a 1: 25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022
October 23, 2022
Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke
September 19, 2022
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model
July 11, 2022
Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis
June 20, 2022
Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022
June 14, 2022
Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZ
June 8, 2022
Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort
May 2, 2022
Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury
April 18, 2022
Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market
April 13, 2022
Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International Conference
April 11, 2022
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
April 10, 2022
Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market
April 10, 2022
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International Convention
March 31, 2022
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance
March 21, 2022
Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat Mastocytosis
March 10, 2022
Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients
February 8, 2022
Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference
February 6, 2022
Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board
January 30, 2022
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer's Disease
January 3, 2022
Decks in 2022
- Investor Presentation (September 2022)
Investor deck · 39 slides · September 2022
- Investor Presentation (April 2022)
Investor deck · 46 slides · April 2022